Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
16 Januar 2024 - 7:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of January 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Emma Walmsley
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.7047
|
7 (partnership shares)
|
|
|
|
£15.7047
|
7 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
14 Ordinary Shares
£15.7047
|
|
e)
|
Date
of the transaction
|
2024-01-10
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Julie Brown
|
|
b)
|
Position/status
|
Chief
Financial Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.7047
|
8 (partnership shares)
|
|
|
|
£15.7047
|
8 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
|
e)
|
Date
of the transaction
|
2024-01-10
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
James Ford
|
|
b)
|
Position/status
|
SVP and
Group General Counsel, Legal and Compliance
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.7047
|
8 (partnership shares)
|
|
|
|
£15.7047
|
8 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
|
e)
|
Date
of the transaction
|
2024-01-10
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Sally Jackson
|
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.7047
|
8 (partnership shares)
|
|
|
|
£15.7047
|
8 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
|
e)
|
Date
of the transaction
|
2024-01-10
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
David Redfern
|
|
b)
|
Position/status
|
President
Corporate Development
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.7047
|
8 (partnership shares)
|
|
|
|
£15.7047
|
8 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
|
e)
|
Date
of the transaction
|
2024-01-10
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Regis Simard
|
|
b)
|
Position/status
|
President,
Global Supply Chain
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.7047
|
8 (partnership shares)
|
|
|
|
£15.7047
|
8 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
|
e)
|
Date
of the transaction
|
2024-01-10
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Phil Thomson
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.7047
|
8 (partnership shares)
|
|
|
|
£15.7047
|
8 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
|
e)
|
Date
of the transaction
|
2024-01-10
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Deborah Waterhouse
|
|
b)
|
Position/status
|
CEO,
ViiV Healthcare and President, Global Health, GSK
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.7047
|
8 (partnership shares)
|
|
|
|
£15.7047
|
8 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
|
e)
|
Date
of the transaction
|
2024-01-10
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Victoria Whyte
|
|
b)
|
Position/status
|
Company
Secretary
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.7047
|
8 (partnership shares)
|
|
|
|
£15.7047
|
8 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
|
e)
|
Date
of the transaction
|
2024-01-10
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Emma Walmsley
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6519
|
22
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Diana Conrad
|
|
b)
|
Position/status
|
Chief People Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6519
|
5
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
James Ford
|
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6519
|
6
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Sally Jackson
|
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6519
|
51
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Luke Miels
|
|
b)
|
Position/status
|
Chief
Commercial Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6519
|
3
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
David Redfern
|
|
b)
|
Position/status
|
President
Corporate Development
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6519
|
62
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Regis Simard
|
|
b)
|
Position/status
|
President,
Global Supply Chain
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6519
|
22
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Phil Thomson
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6519
|
38
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Deborah Waterhouse
|
|
b)
|
Position/status
|
CEO,
ViiV Healthcare
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6519
|
51
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Victoria Whyte
|
|
b)
|
Position/status
|
Company
Secretary
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6519
|
46
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dylan Jackson
|
|
b)
|
Position/status
|
PCA of Ms S Jackson (SVP, Global Communications and CEO
Office)
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.7208
|
21
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Iain Whyte
|
|
b)
|
Position/status
|
PCA of Ms V Whyte (Company Secretary)
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.7208
|
903
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2024-01-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
David
Redfern
|
|
b)
|
Position/status
|
Chief
Strategy Officer
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 11 January 2024, on Ordinary Shares held
within an ISA
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6989
|
17
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date of
the transaction
|
2024-01-12
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Victoria
Whyte
|
|
b)
|
Position/status
|
Company
Secretary
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 11 January 2024, on Ordinary Shares held
within an ISA
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.6989
|
14
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date of
the transaction
|
2024-01-12
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Elizabeth
McKee Anderson
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$40.1022
|
8
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date of
the transaction
|
2024-01-12
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Charles
Bancroft
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$40.1022
|
46
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date of
the transaction
|
2024-01-12
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Dr Hal
Barron
|
|
b)
|
Position/status
|
Non-Executive
Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$40.1022
|
11
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date of
the transaction
|
2024-01-12
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Dr Anne
Beal
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$40.1022
|
6
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date of
the transaction
|
2024-01-12
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Dr
Harry Dietz
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$40.1022
|
6
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date of
the transaction
|
2024-01-12
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Dr
Jesse Goodman
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$40.1022
|
6
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date of
the transaction
|
2024-01-12
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Dr
Vishal Sikka
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$40.1022
|
32
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date of
the transaction
|
2024-01-12
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: January
16, 2024
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
GSK (NYSE:GSK)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
